NYSE$PRGO
Perrigo Company · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported fourth quarter and fiscal year 2021 financial results.
Perrigo's fourth quarter net sales grew by 4.9% to $1.1 billion, driven by a strong rebound in demand for cough/cold products. The company's transformation into a focused, consumer-centric Self-Care company is now complete and their focus going forward is on long-term, profitable growth.
- Fourth quarter net sales grew 4.9%, or 5.7% excluding the impact of currency, compared to the prior year to $1.1 billion led by a strong rebound in the demand for cough/cold products.
- Fourth quarter GAAP (reported) diluted earnings per share (EPS) was $0.24, compared to a net loss per diluted share of $0.39 in the prior year.
- Fourth quarter non-GAAP (adjusted) diluted EPS increased 27.7% to $0.60.
- Completed milestone transformation initiatives during 2021: Divested the generic RX pharmaceutical business, announced the acquisition of HRA Pharma, and significantly reduced uncertainty by settling the Irish Tax assessment.
Headline financials
Revenue & EPS history
Perrigo · Revenue · Quarterly
$1.1B
Revenue by segment
Perrigo · $1.1B total across 2 segments · Q4 2021
- Consumer Self-Care Americas$736M+5.0%66.6%
- Consumer Self-Care International$369M+4.8%33.4%
Forward guidance
The Company expects net sales growth of 3.5% to 4.5%, inclusive of negative impacts of approximately 2.0 percentage points from the planned divestiture of the Latin American businesses and 1.5 percentage points from adverse currency movements, Organic net sales growth of 7.0% to 8.0%, Adjusted diluted EPS of $2.10 to $2.30.
Tailwinds
- Net sales growth of 3.5% to 4.5%
- Organic net sales growth of 7.0% to 8.0%
- First half margin compression and second half margin expansion
- Adjusted effective tax rate of approximately 23%
- Adjusted diluted EPS of $2.10 to $2.30
Headwinds
- Negative impacts of approximately 2.0 percentage points from the planned divestiture of the Latin American businesses
- 1.5 percentage points from adverse currency movements
- First half margin compression
- Higher level of cost inflation
- COVID-19 related productivity challenges
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-1.5%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-3.4%
Avg return
30 days after
48%
30 / 63 earnings
Positive
+20.2%
Q4 2024
Best reaction
-25.2%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.3% | -5.0% | -7.0% | |
| Q4 2025 | -1.5% | -21.0% | -33.9% | |
| Q3 2025 | -25.2% | -29.4% | -33.4% | |
| Q1 2025 | +7.2% | +9.4% | +6.0% | |
| Q4 2024 | +20.2% | +22.1% | +16.3% | |
| Q3 2024 | +6.2% | +5.4% | +10.7% | |
| Q2 2024 | +1.8% | -1.5% | +3.3% | |
| Q1 2024 | -6.9% | -8.1% | -19.2% | |
| Q4 2023 | -17.9% | -18.2% | +0.1% | |
| Q3 2023 | +2.0% | -0.2% | +7.3% | |
| Q2 2023 | +5.8% | +7.3% | -8.4% | |
| Q1 2023 | +1.3% | -2.2% | -6.5% | |
| Q4 2022 | +3.9% | +6.9% | -3.2% | |
| Q3 2022 | -18.3% | -14.9% | -18.2% | |
| Q2 2022 | -1.9% | -1.7% | -9.3% | |
| Q1 2022 | +9.1% | +15.6% | +19.7% | |
| Q4 2021 | +6.4% | +4.8% | +8.2% | |
| Q3 2021 | -8.7% | -9.8% | -23.0% | |
| Q2 2021 | -16.0% | -16.6% | -11.1% | |
| Q1 2021 | +6.1% | +6.4% | +13.3% | |
| Q4 2020 | +4.3% | +1.7% | +0.3% | |
| Q3 2020 | -0.3% | +1.5% | +9.9% | |
| Q2 2020 | -8.5% | -6.1% | -7.7% | |
| Q1 2020 | -3.0% | -4.4% | +0.8% | |
| Q4 2019 | -16.4% | -12.1% | -24.0% | |
| Q3 2019 | -8.1% | -9.3% | -3.4% | |
| Q2 2019 | -7.1% | -5.4% | -1.1% | |
| Q1 2019 | +7.5% | +1.7% | -10.1% | |
| Q4 2018 | +0.8% | +4.0% | -0.3% | |
| Q3 2018 | -14.7% | -13.0% | -20.2% | |
| Q2 2018 | -10.7% | -11.3% | -3.3% | |
| Q1 2018 | -4.9% | +0.4% | -5.2% | |
| Q4 2017 | +1.9% | -6.0% | -5.6% | |
| Q3 2017 | +8.0% | +5.9% | +5.4% | |
| Q2 2017 | +18.3% | +17.2% | +24.7% | |
| Q1 2017 | +4.1% | +5.0% | +8.5% | |
| Q3 2016 | +6.9% | +6.7% | -1.2% | |
| Q2 2016 | -9.8% | -7.2% | -6.7% | |
| Q1 2016 | -4.7% | — | — | |
| Q4 2015 | -10.9% | — | — | |
| Q3 2015 | -1.3% | — | — | |
| Q2 2015 | +1.7% | — | — | |
| Q1 2015 | -1.7% | — | — | |
| Q4 2014 | +6.7% | — | — | |
| Q3 2014 | -11.3% | — | — | |
| Q2 2014 | -4.9% | — | — | |
| Q1 2014 | +10.7% | — | — | |
| Q4 2013 | -5.1% | — | — | |
| Q3 2013 | -0.5% | — | — | |
| Q2 2013 | +5.2% | — | — | |
| Q1 2013 | -8.8% | — | — | |
| Q4 2012 | -8.3% | — | — | |
| Q3 2012 | -4.5% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q2 2012 | -0.1% | — | — | |
| Q4 2011 | +1.3% | — | — | |
| Q3 2011 | -7.6% | — | — | |
| Q2 2011 | +2.7% | — | — | |
| Q1 2011 | +1.7% | — | — | |
| Q4 2010 | +0.6% | — | — | |
| Q3 2010 | -0.1% | — | — | |
| Q2 2010 | -2.9% | — | — | |
| Q1 2010 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro